Moexipril
This ACE inhibitor lowers blood pressure by blocking the enzyme that converts angiotensin I to the potent vasoconstrictor angiotensin II, causing blood vessels to relax and the kidneys to excrete more sodium and water. It is used to treat high blood pressure and may have additional cardiovascular protective effects.
Molecular Weight
498.6000 g/mol
LogP
1.20
TPSA
114.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
2D Structure
Cite this structure
Embed this structure
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
Molecular Formula
C27H34N2O7
HBD / HBA
2 / 8
Rotatable Bonds
12
Heavy Atoms
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This ACE inhibitor lowers blood pressure by blocking the enzyme that converts angiotensin I to the potent vasoconstrictor angiotensin II, causing blood vessels to relax and the kidneys to excrete more sodium and water. It is used to treat high blood pressure and may have additional cardiovascular protective effects.
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Yes, Moexipril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1165. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 91270. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="moexipril"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/moexipril/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/moexipril/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/moexipril/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="moexipril"></drugfyi-drug>